Selective acceptance of MHC class I-deficient tumor grafts in the brain
- PMID: 3346626
- PMCID: PMC2188854
- DOI: 10.1084/jem.167.2.730
Selective acceptance of MHC class I-deficient tumor grafts in the brain
Abstract
H-2-deficient (H-2-) tumor variants were accepted equally well compared with H-2+ wild-type cells in the brain of syngeneic mice, while the H-2- cells were selectively eliminated when inoculated extracranially. This indicates a specific absence or suppression of the defense against MHC class I-deficient cells in the brain, suggested to be mediated by NK cells. In contrast, T cell-mediated immune reactions could clearly be detected in the brain under the same experimental conditions. This was shown in control experiments where H-2+ tumor cells were rejected from the brain of preimmunized or allogeneic mice. The present findings may be important for the understanding of neurotropic virus infections, immunology and immunotherapy of brain tumors, as well as for the growing interest in tissue grafting within the central nervous system.
Similar articles
-
Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.J Immunol. 1998 Jan 15;160(2):572-9. J Immunol. 1998. PMID: 9551890
-
Natural resistance against tumors grafted into the brain in association with histocompatibility-class-I-antigen expression.Int J Cancer. 1996 Jul 29;67(3):365-71. doi: 10.1002/(SICI)1097-0215(19960729)67:3<365::AID-IJC10>3.0.CO;2-7. Int J Cancer. 1996. PMID: 8707410
-
[Experimental analysis of intracerebral natural resistance against H-2+ and H-2- lymphomas grafted into the brain].No Shinkei Geka. 1989 Aug;17(8):717-23. No Shinkei Geka. 1989. PMID: 2586713 Japanese.
-
Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.Cancer Res. 1995 May 1;55(9):1911-6. Cancer Res. 1995. PMID: 7728758
-
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.
Cited by
-
Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.Immunol Res. 1990;9(4):298-313. doi: 10.1007/BF02935529. Immunol Res. 1990. PMID: 2089075 Review. No abstract available.
-
Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self" recognition.Immunogenetics. 2017 Aug;69(8-9):547-556. doi: 10.1007/s00251-017-1011-9. Epub 2017 Jul 11. Immunogenetics. 2017. PMID: 28699110 Free PMC article. Review.
-
Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients.J Neurooncol. 1994;20(1):47-53. doi: 10.1007/BF01057960. J Neurooncol. 1994. PMID: 7807183
-
Intracerebral inflammatory response to experimental brain contusion.Acta Neurochir (Wien). 1995;132(1-3):110-9. doi: 10.1007/BF01404857. Acta Neurochir (Wien). 1995. PMID: 7754844
-
Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene.J Exp Med. 1993 Jan 1;177(1):201-5. doi: 10.1084/jem.177.1.201. J Exp Med. 1993. PMID: 8418201 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials